

CERVICAL VIRAL INFECTION CAUSES PREMATURE CERVICAL RIPENING IN A  
MOUSE MODEL OF PREGNANCY

By

Devin McGee

A THESIS

Submitted to  
Michigan State University  
in partial fulfillment of the requirements  
for the degree of

Animal Science—Master of Science

2017

## ABSTRACT

### CERVICAL VIRAL INFECTION CAUSES PREMATURE CERVICAL RIPENING IN A MOUSE MODEL OF PREGNANCY

By

Devin McGee

Preterm birth (PTB), or birth before 37 weeks of gestation, occurs in about 1 in every 10 pregnancies in the United States and is the leading cause of neonatal morbidity and mortality in the developed world. Furthermore, surviving preterm infants are at increased risk for brain, heart, breathing, metabolic, and immune function problems, with an estimated cost of \$26 billion each year. Despite the health and financial implications of PTB, 50% of cases still have no attributed cause. Recently, cervical viral infection has been identified as a risk factor for PTB. The implication of viruses, specifically herpes simplex virus-2 (HSV-2), in pregnancy outcomes has not been well defined. Our approach was to utilize both in vivo and in vitro models to study cervical viral infection. Using a mouse model of pregnancy, we determined that intra-vaginal HSV-2 infection resulted in changes in both cervical structure and function. Viral infection caused stromal disorganization and increased risk for PTB associated with ascending bacterial infection. Using a cervical epithelial cell line, we discovered HSV-2 mediated changes in cell function by activating Src kinase, which affected hormone receptor stability and other down-stream effectors. We conclude that viral infection of the cervix leads to alterations in key pathways that are important to parturition and ultimately increase risk for PTB.

Copyright by  
DEVIN MCGEE  
2017

Dedicated to my Mom for instilling a sense of wonder and appreciation for how all things work and to my Dad for challenging me to be well-informed in what I discuss, and to think critically.

## ACKNOWLEDGEMENTS

I would like to thank my mentor Dr. Karen Racicot for all the time, effort, and patience she gave me as she helped me grow both as scientist, and as a hard-working student. I want to thank Dr. Arianna Smith for keeping me sane by making me laugh every day and for putting up with my shenanigans. A special thanks to Sharra Poncil is necessary for teaching me many of the techniques I utilized in the lab. I also want to acknowledge and thank my committee members Dr. Fazleabas, Dr. Petroff, and Dr. Knott for their time and for their support and advice. Dr. Knott also helped me by allowing me lab space and equipment for a semester in East Lansing which I am very grateful for as it keep me off the snowy roads! A thank you is necessary to each of Dr. Rooney and Chris Svoboda from Michigan State's Geology Department for their generous time and space to allow me to borrow a special microscope to image a critical part of my work. I thank the members of the Teixeira lab in Grand Rapids for the advice and unselfish sharing of space. And finally, I want to thank my friends, family, and relatives for their words of encouragement and support as I pursued my degree.

## TABLE OF CONTENTS

LIST OF FIGURES.....	vii
KEY TO ABBREVIATIONS.....	viii
CHAPTER 1: REVIEW OF THE LITERATURE.....	1
Significance of Preterm Birth.....	2
Risk Factors for Preterm Birth.....	3
The Function of the Cervix During Pregnancy.....	3
Cervical Softening.....	4
Cervical Ripening.....	5
Hormonal Regulation of Cervical Ripening.....	6
Immune Regulation of Cervical Ripening.....	8
Cervical Viral Infections and PTB.....	10
Herpes Simplex-2 Virus.....	11
CHAPTER 2: CERVICAL VIRAL INFECTION CAUSES PREMATURE CERVICAL RIPENING IN A MOUSE MODEL OF PREGNANCY.....	13
Abstract.....	14
Introduction.....	15
Materials and methods.....	18
Pregnant mice and infections.....	18
Histology.....	18
Cell culture and treatments.....	19
Virus production and quantification.....	20
RNA, cDNA synthesis and qPCR.....	20
Hyaluronic Acid ELISA.....	21
Western blot analysis.....	22
Statistical analysis.....	22
Results and figures.....	23
Cervical viral infection affects stromal tissue organization.....	23
Viral infection increases ER- $\alpha$ protein in cervical epithelial cells.....	26
Hyaluronic acid is increased by HSV-2 in the pregnant cervix and ECT1 cells.....	28
Herpes simplex virus-2 activation of Src kinase stabilizes ER- $\alpha$ and regulates HA.....	30
Hyaluronic acid mediates HSV-2 infection.....	33
CHAPTER 3: CONCLUSIONS AND DISCUSSION .....	35
REFERENCES.....	42

## LIST OF FIGURES

Figure 1: Cervical viral infection affects stromal tissue organization.....	24
Figure 2: Viral infection increases ER- $\alpha$ protein in cervical epithelial cells.....	27
Figure 3: Hyaluronic acid is increased by HSV-2 in the pregnant cervix and ECT1.....	29
Figure 4: Herpes simplex virus-2 regulates ER- $\alpha$ and HA via Src kinase activation.....	31
Figure 5: Hyaluronic acid mediates HSV-2 infection.....	34
Figure 6: Proposed model of cervical viral infection during pregnancy.....	40

## KEY TO ABBREVIATIONS

PTB	Preterm Birth
Src	Src Kinase
4-MU	4-Methylumbelliferone
IVAG	intravaginal
sPTB	Spontaneous preterm birth
Src	Src kinase
ER $\alpha$	Estrogen Receptor Alpha
i.p.	intraperitoneal
IVAG	intravaginal
SKI	Src Kinase inhibitor
PP1	Src Kinase inhibitor
C.I.	Cervical insufficiency
E.O.	External orifice
TFF1	Trefoil factor 1
SPINK5	Serine protease inhibitor Kazal type 5
GAG	Glycosaminoglycans
MMP	Matrix metalloproteinases
PG	Prostaglandins
PGE2	Prostaglandin E2
HA	Hyaluronic acid or Hyaluronan
HAS	Hyaluronic acid synthase

MW	Molecular weight
KO	Knockout
17 $\beta$ HSD	17 $\beta$ -hydroxysteroid dehydrogenase type 2
20 $\alpha$ HSD	20 $\alpha$ -hydroxy-steroid dehydrogenase
5 $\alpha$ -SRD	Steroid 5 $\alpha$ -reductase
HPV	Human Papilloma Virus
HSV-2	Herpes Simplex Virus type 2
HSV-1	Herpes Simplex Virus type 1
MHV	Murid Herpes Virus
LPS	Lipopolysaccharide
IFN	Interferon
NK	Natural Killer Cells
pDC	plasmacytoid dendritic cells
PR	Pregesterone receptor
<i>PgR</i>	Progesterone receptor gene
P <sub>4</sub>	Progesterone
ECM	Extracellular matrix
E <sub>2</sub>	17 beta-estradiol
DME	Differentiated mucosal epithelial cells
NDE	Non-differentiated mucosal epithelial cells
SFK	Src Family Kinases
Gd	Gestational day
MHV	Murid Herpesvirus

CMV	Cytomegalovirus
HHV	Human Herpes virus
EBV	Epstein-Barr virus
Tyr	Tyrosine residue
DMSO	Dimethyl sulfoxide
ANOVA	Analysis of Variance
n.s.	Not significant

**CHAPTER 1:**  
**REVIEW OF THE LITERATURE**

### Significance of Preterm Birth

Preterm birth (PTB), or birth before 37 weeks of gestation, accounts for over 10% of all pregnancies worldwide and over 11% in the United States[1-4] and rates continue to rise, despite continued attempts at intervention [5] [6, 7]. Preterm delivery is the leading cause of neonatal morbidity and mortality resulting in nearly 1 million neonatal deaths per year [4, 8, 9]. These deaths stem from preterm infants' increased risk for neurologic and developmental disabilities [10], respiratory distress [11], dysregulated metabolism function [12], bone disease [13], heart defects [14], and immune function impairment [15]. Many of these problems arise because preterm infants have underdeveloped organs or organ systems [11]. Even when preterm infants survive past 5 years of age, they typically have poor long-term outcomes that include higher risk for vision and hearing impairment, chronic lung diseases, cardiovascular diseases, brain development and behavior problems such as increased hyperactivity, anxiety, and depression [16].

The cost associated with caring for a preterm infant is, understandably, quite high. The Institute of Medicine's Committee on Understanding Premature Birth and Assuring Healthy Outcomes found that the *minimum* cost burden of PTB on the US economy is predicted to be 26.2 billion dollars per year with 5.7 billion of that total coming from the disabilities associated with PTB. These estimates only consider four major debilitating conditions: cerebral palsy, mental retardation, vision impairment, and hearing loss; therefore, the estimates could be missing a significant amount of cost. Furthermore, the average cost per infant born preterm is about \$51,600 [16], which can be an incredible financial burden to a new family, especially to an uninsured family.

Unfortunately, research to understand and prevent PTB is underfunded [17] and there is still much to learn about the causes and mechanism(s) of PTB [17].

### *Risk Factors for Preterm Birth*

Bacterial infections and cervical insufficiency have been identified as important risk factors for PTB [18-20]. Up to 40% of preterm births are associated with intra-uterine infection [21] and, intra-vaginal, intra-uterine and/or systemic injection with bacteria or their conserved microbial motifs can induce PTB in animal models [22-28]. The majority of intra-uterine infections ascend from the vagina [29], and this is associated with cervical insufficiency [30]. Cervical insufficiency (CI) is characterized as mechanical weakness of the cervical tissue that affects the capacity of the cervix to support the fetus, and protect it from bacteria in the lower reproductive tract [31]. Unfortunately, diagnosing cervical insufficiency is challenging because of the limited criteria for use by clinicians [31]. While factors such as “short cervix” can be used as indicators of CI, by this time PTB is typically inevitable [32, 33].

### *The Function of the Cervix During Pregnancy*

Throughout gestation the cervix functions as a structural and immune barrier for the developing fetus. During pregnancy, the cervical stroma is characterized by a dense extracellular matrix of proteins, including highly cross-linked fibrillar collagen, which provides mechanical strength to the tissue [34]. In humans and rodents, the cervical lumen is lined by epithelial cells that generate a cervical mucus plug, which

provides physical and immune protection against the vaginal flora [35-37]. At the end of gestation, the cervix must undergo a significant transformation into a pliable tissue to allow for the fetus to pass through the vaginal canal. The changes in the cervical structure, or “cervical remodeling”, is a tightly regulated process that can be grouped into two different stages: cervical softening and cervical ripening [38].

### Cervical Softening

In mid-gestation the cervix begins undergoing structural changes, appropriately named “cervical softening” by Dr. Word and colleagues, resulting in a progressively more compliant tissue but without loss of its mechanical competence [39]. In women softening begins at the end of the first trimester, and in mice is initiated by day 12 [39, 40]. Cervical softening is associated with decreased collagen cross-linking in the cervical stroma [41]. Collagen undergoes continuous turn-over, and during this time there is a down-regulation of genes, such as *Plod2* [41], that mediate the formation of the cross-linked collagen [42]. There are also changes in cervical epithelial cell function that could affect the characteristics of the cervical mucus barrier [38, 39]. For example, trefoil factor 1 (TFF1) and serine protease inhibitor Kazal type 5 (SPINK5) proteins incrementally increase in the epithelia during softening [39]. Trefoil factor 1 is an estrogen-regulated peptide, secreted by mucosal cells, that has a role in mucosal protection and epithelial repair [43]. The protease inhibitor encoded by SPINK5 also functions to maintain the epithelial barrier [44]. Increased expression of factors that protect the epithelial barrier is understandably important in preparation for vaginal

delivery. However, it is not known how changes in these factors or others affect the mucosal protection against bacteria.

### Cervical Ripening

Over the last 2-3 days of gestation in the mouse, or in the last weeks of pregnancy in women, the cervix enters the phase of “cervical ripening” resulting in complete structural reorganization of the cervical stroma in preparation for labor. The stromal compartment becomes increasingly hydrated and the collagen fibers become larger in diameter and increasingly disorganized, a process initiated during cervical softening [41]. The changes in collagen structure are associated with increased collagen solubility, decreased cross-linking and down-regulation of collagen accessory proteins such as thrombospondin-2 and tenascin C [41]. Collagen degradation can also result from activation of matrix metalloproteinases in fibroblasts and activated immune cells [45].

Cervical ripening is also associated with changes in ECM components such as proteoglycans [46, 47]. Proteoglycan metabolism increases before the onset of labor in the term cervix and in preterm labor and elastin is low in women with cervical insufficiency [46, 47]. Interestingly, versican, decorin, and heparan sulphate are proteoglycans that are highly expressed in the cervix, but don't change over the course of pregnancy [39, 48]. Perhaps what is more important than their regulation or expression is their interaction with other components in the cervix. These factors could still regulate cervical structure and function via their interactions with collagen or immune cell recruitment [38, 49]. For example, decorin can cause an increase in collagen fibrils and versican can also affect ECM disorganization in tissue remodeling

[50]. Heparan sulphate can interact with cytokines, such as IL-8 [49, 51], and can affect their half-life and functional potency within the tissue [52-54].

Hyaluronan, also known as Hyaluronic acid (HA), is a non-sulfated glycosaminoglycan that is a component of the ECM of most tissues [55]. It has been shown to affect tissue hydration [56], collagen interactions [57], and the immune response [58]. Hyaluronan is produced by epithelial, stromal, and immune cells in the cervix [55], then excreted into the ECM in multiple forms, ranging from high molecular weight (MW) HA, thought to influence tissue structure, and low molecular weight HA, potentially mediating tissue repair or the immune response [59]. It is present in the cervix in low amounts throughout pregnancy, but drastically increases during cervical ripening when the hyaluronan synthase enzyme gene, *Has2*, is upregulated [55, 60]. The HA that increases during ripening is high molecular weight, and has been implicated in weakening fibronectin-collagen interactions, thus destabilizing the ECM and making collagen vulnerable to collagenases [61]. Interestingly, when HA function was studied in the pregnant cervixes of HA knockout mice, it was determined to have a role in epithelial and mucosal barrier function against pathogenic *E. coli* [62]. Indeed, loss of HA resulting in increased ascending bacterial infection and higher rates of infection-associated PTB[62].

### Hormonal Regulation of Cervical Ripening

Cervical ripening is associated with the functional loss of progesterone (P<sub>4</sub>) signaling within the cervix. Cervical ripening can be induced in women and rodents by

anti-progestin treatment, and vaginal P<sub>4</sub> can delay ripening and labor in women with anatomically short cervix [63]. Interestingly, the loss of cervical P<sub>4</sub> does not appear to be a result of declining P<sub>4</sub> in the circulation. In women, circulating P<sub>4</sub> does not significantly decrease before labor. In rodents, circulating P<sub>4</sub> does decline before labor, but cervical ripening is initiated prior to the decline [64]. Therefore, it is postulated that loss of P<sub>4</sub> function in the cervix is the result of tissue-specific changes in P<sub>4</sub> concentration and/or function [65]. The loss of P<sub>4</sub> function in the cervix preceding cervical ripening is not well defined but elegant work has demonstrated that there are changes in local P<sub>4</sub> metabolism.

Enzymes that metabolize progesterone and estradiol are expressed by cervical cells and are regulated over gestation. Enzymes that convert P<sub>4</sub> to an inactive form increase during ripening while enzymes that synthesize estradiol (E<sub>2</sub>) increase at this time [66]. For example in early pregnancy, epithelial cells express 17 $\beta$ -hydroxysteroid dehydrogenase-2 (17 $\beta$ -HSD-2), which catalyzes the conversion of estradiol to inactive estrone. It also oxidizes its partner enzyme, 20 $\alpha$ -HSD, which maintains progesterone concentrations. During cervical ripening, 17 $\beta$ -HSD is downregulated in epithelial cells, resulting in decreased local progesterone and increased estradiol [66-68]. The expression of the enzyme steroid 5 $\alpha$ -reductase (5 $\alpha$ -SRD) also converts progesterone to an inactive form and is upregulated in the cervical epithelia of mice during ripening. Indeed, 70% of mice lacking 5 $\alpha$ -SRD had delayed parturition because local progesterone remained high, resulting in the inability to undergo cervical ripening [69]. Interestingly, there is little known about the role of estrogen in cervical ripening, although several studies suggest potential functions. For example, it was previously determined that estrogen administration induced cervical collagenase activity in women and rodents,

which could potentially affect collagen remodeling [70-73]. In vitro models have also demonstrated that estrogen induces collagen degradation activity, which can be blocked by progestin treatment [73, 74]. The key enzyme responsible for up-regulation of cervical HA during ripening, HAS2, is also regulated by estradiol [75], suggesting a role in HA-mediated immune protection.

### *Immune Regulation of Cervical Ripening*

Immune cell recruitment, pro-inflammatory cytokines, prostaglandins and protease activation are also implicated in the regulation of cervical ripening. It is proposed that activated immune cells induce ripening by expressing proteases that degrade collagen and cytokines that affect tissue hydration [76]. These cells are also potential sources of prostaglandins, which regulate progesterone and induce labor [77-79]. There is some debate about the role of inflammation in the regulation of ripening. Some propose that infection induces cervical ripening via an inflammatory mechanism [80], and this is distinct from the mechanism associated with the functional loss of local progesterone.

Graham Liggins (1981) initially theorized cervical ripening was an inflammatory reaction mediated by immune cells [81]. It was postulated that neutrophils infiltrated during cervical ripening and mediated collagen degradation by secreting MMPs [82-85]. Recent studies, however, suggest neutrophils might have a more important role in cervical repair, postpartum [86-88]. These studies found that women and mice did not have increased neutrophils in the cervix at ripening, but they were increased postpartum [87, 88]. Also, depletion of neutrophils did not affect ripening or parturition in

mice, and there was no increase in myeloperoxidase, a marker of neutrophil function, until the period of post-partum repair [86, 88].

Monocyte recruitment and macrophage activation have also been characterized in the cervix during cervical ripening, although there is debate about the origin of these cells and how they function. Some have reported monocyte recruitment to the cervix during cervical ripening in mice, but without increased differentiated macrophages [89]. These data have led some to suggest that, like neutrophils, the role of macrophages is in post-partum cervical repair [38, 88]. Others have reported increased macrophage numbers and changes in functional markers at the time of cervical ripening, in direct conflict with the prior reports [90, 91]. In addition, macrophage depletion was able to prevent LPS-induced preterm birth in a mouse model [92]. These discrepancies are most likely associated with different methodologies, as evidenced by an elegant report from Steve Yellon's laboratory. They determined that if the cervixes of mice were perfused prior to tissue collection and dispersion there was no increase in monocyte numbers. This observation suggested increased monocyte numbers previously reported were likely a result of the increased cervical vasculature, not a specific recruitment to the tissue. They also performed highly validated, 8-marker flow cytometric analysis of macrophage populations within the cervix, including markers for cell viability and activation. They discovered robust changes in functional populations of macrophages associated with ripening, supporting a potential role for these cells prior to post-partum repair.

### Cervical Viral Infections and PTB

An increasing number of clinical studies suggest that cervical viral infection is a risk factor for PTB. Meta-analysis of Human Papilloma Virus (HPV) infections and preterm birth showed that HPV infections could more than double risk for preterm delivery [93]. This is important because, while HPV vaccines are used to combat cervical dysplasia and cancer, the HPV vaccine may provide an additional obstetrical benefit, and screens for HPV could be used as a predictor for PTB [93]. Several recent studies have also linked HSV-2 infections with increased risk for PTB, including a study with nearly 700,000 women that showed untreated genital HSV-2 infection nearly doubled the risk for PTD [94]. Another study in 2017 confirmed treatment of genital herpes with acyclovir decreased the chances of preterm birth in a cohort of with HSV-2 positive women in Uganda [95]. Early evidence of HSV-2's relationship to preterm birth was found in a 1996 study that associated asymptomatic genital shedding of the virus with increased incidence of preterm delivery [96]. Despite these associations there have been few studies into the mechanistic role that HSV-2 may have in incidences of preterm deliveries.

A mouse model of viral infection during pregnancy also suggests that cervical viral infection increases risk of PTB in the presence of bacteria. This mouse model was developed using a gammaherpes virus, MHV68, a latent DNA virus from the *herpesviridae* family, the same family of nearly all of the viruses that infect the woman's reproductive tract (HSV, CMV, EBV, HHV6, HHV7). When pregnant mice received an intraperitoneal (i.p.) injection of MHV68 on embryonic day (E)8.5 of pregnancy it

sensitized the response to a secondary i.p. injection of LPS on E15.5, resulting in PTB [97]. The same dose of LPS on that day did not induce PTB in mice without viral infection [97]. This suggested that while viral infection, alone, was not enough to induce labor, it acted as a “risk factor” to those with a secondary infection. **Importantly,** the pregnant cervix was the primary reproductive tract target for MHV68, and infection affected cervical function by decreasing cervical protection against ascending bacterial infections. This suggests the mouse can be a reasonable model for herpes viral-infection associated PTB, which is generally associated with cervical HSV-2 infection in women.

### *Herpes Simplex-2 Virus*

The *Herpesviridae* family is a large group of double-stranded DNA viruses that are ubiquitous in the human population [98-101]. Herpes Simplex Virus (HSV) -1 is predicted to be present in 67% of the world’s population [98], and HSV-2 in over 11% [99]. HSV-2 generally manifests as a genital infection, and has received special attention during pregnancy for the its potential for vertical transmission from mother to neonates [99, 100]. HSV-1 remains important since there has been a rising number of genital herpes cases documented as being caused by HSV-1 [102].

HSV-2 poses a unique problem for its host because, after an infection episode, it has the ability to establish latency within neurons and later reactivate in a lytic cycle [103]. HSV-2 primarily and efficiently infects mucosal epithelial cells, which is the classical site of primary infection and HSV is also present in these cells during its lytic cycle which is essential for transmission [104]. HSV-2 targets sensory neurons for long term residency, important for its latent life [104]. There are a few well documented

stimuli that induce reactivation of viruses including UV light exposure, emotional stress, fever, tissue damage, and immune suppression [103]. HSV-2 also has documented cases of lytic cycles, which result in viral shedding, occurring without the presence of clinically noticeable symptoms, and this is postulated to be why HSV-2 is so effective in its virulence [105-108].

Herpes simplex virus -2 is an enveloped virus that utilizes host cell surface receptors for attachment and subsequent breach of cells [109]. Herpes simplex virus has been shown to bind to glycosaminoglycans and interacts with plasma membrane integrin  $\alpha\beta 3$  for entry into genital tract epithelial cells [109, 110]. Interestingly, HSV-2 causes phosphorylation of the integrin's downstream focal adhesion kinase even in the absence of viral entry [109]. Specifically, herpes viruses have been shown to regulate Src family kinase activity as a means of producing efficient viral yields [111, 112]. It is not known how these cellular changes might affect the cervical epithelial cells in the context of pregnancy.

## **CHAPTER 2:**

# **CERVICAL VIRAL INFECTION CAUSES PREMATURE CERVICAL RIPENING IN A MOUSE MODEL OF PREGNANCY**

## **Abstract**

Preterm birth occurs in about 10% of all pregnancies worldwide, and about 12% of pregnancies in the United States. Preterm infants have an increased risk for brain, heart, breathing, metabolism, and immune function problems, which is, in-part, why it is the leading cause of neonatal morbidity and mortality in the developed world. 50% of all spontaneous PTB cases have no cause attributed to them. Viruses, specifically HSV-2, have been implicated in potentially contributing to preterm delivery (PTD) and require a deeper examination. In order to do this, we utilized both an in vivo mouse model and in vitro cell line model of virus infections to study both outcomes and mechanisms by which the virus acts on cervix tissue and cells. We observed that intravaginal infections with HSV-2 of our pregnant E15.5 mice show cervixes with characteristics of cervical insufficiency compared to controls. Viral infection of both mice and ECT1 cells with HSV-2 results in a stabilization of the transcription factor estrogen receptor alpha (ER $\alpha$ ) which is mediated by the focal adhesion kinase, Src. We also found an upregulation of progesterone receptor (PR) in our virally treated mice cervixes. ELISA analysis of hyaluronic acid (HA) showed that it is upregulated in response to viral infection in mice cervical flushes and human cervical epithelial cells. HA was linked as an important factor for high viral copy numbers, and to the focal adhesion kinase, Src, by its downregulation when pSrc is inhibited. Our results show that intravaginally infected mice by E15.5 show characteristics of cervical insufficiency (i.e. dilute collagen, tissue spacing) and HSV-2 infected cervical cells show increases in factors important for parturition suggesting that viral infections of the cervix could contribute to compromised cervix integrity, and subsequent preterm labor.

## Introduction

Preterm birth (PTB), or birth before 37 weeks' gestation, affects approximately 12% of pregnancies in the United States [9, 113-118] and is the leading cause of neonatal mortality worldwide. Unfortunately, there has been little progress in predicting, preventing and treating PTB due to the complexity of the condition. Indeed, PTB is more accurately defined as a syndrome, resulting from an accumulation of risk factors that, in isolation, may not precipitate labor [114]. While some risk factors have been identified, including infection/inflammation, low progesterone (P<sub>4</sub>), cervical insufficiency, and race/ethnicity, we have had limited success using them to predict PTB. Furthermore, nearly half of PTB have no known risk factors and are unexplained. Therefore, the best strategy for predicting or preventing PTB will be to identify the common biological pathways that can be influenced by multiple risk factors.

Appropriate regulation of cervical structure and function is essential to pregnancy maintenance. Throughout most of gestation, the cervical stroma contains a dense extracellular matrix (ECM) rich in highly organized fibrillar collagen. This provides structural support for the developing fetus [119]. The cervical epithelial cells also synthesize a highly effective mucus barrier that protects the uterus from ascending bacteria. This barrier consists of mucins, proteoglycans, anti-microbial peptides, cytokines, proteases and associated protease inhibitors [120]. At the end of gestation there is profound remodeling of the stromal ECM resulting in a structurally compliant tissue in preparation for vaginal birth. At this time the collagen fibers become larger in diameter and increasingly disorganized as a result of increased collagen solubility, decreased cross-linking, increased stromal hydration and/or enzymatic degradation [39].

There are also significant changes in the mucus barrier and epithelial cell function. Collectively, this process is termed “cervical ripening”, and premature cervical ripening precedes preterm labor.

The initiation and regulation of ripening is not well-understood, but there is evidence it is influenced by a tissue-specific decline in progesterone ( $P_4$ ) concentration and/or function[65]. Cervical ripening can be induced in women and rodents by anti-progestin treatment, and vaginal  $P_4$  can delay ripening and labor in women. Changes in  $P_4$  concentration could be mediated by an increase in local  $P_4$  metabolism or changes in the expression of steroid hormone receptors genes for  $P_4$  and  $E_2$  (*PgR/ESR1*). Interestingly, very little is known about the role of  $E_2$  in cervical ripening.

Ripening is also associated with increased synthesis of hyaluronan (HA). The function of HA in the pregnant cervix is not fully understood, but it has been identified as an important mediator of epithelial cell differentiation, epithelial barrier permeability and ascending bacterial infections [121]. The concentration and size of HA may also affect stromal remodeling. High molecular weight (HMW) HA increases in the stroma during ripening, and may contribute to ECM disorganization and loosening because of its large size (>500 kDa) and high level of glycosylation [60].

One of the most common causes of PTB is ascending bacterial infection, which typically indicates cervical function is compromised. Normally, cervical epithelial cells synthesize a highly effective mucus barrier that protects the uterus from ascending bacteria. This barrier consists of mucins, proteoglycans, anti-microbial peptides, cytokines, proteases and associated protease inhibitors. During cervical ripening there is increased epithelial cell proliferation [122], increased synthesis of hyaluronan (HA) [55],

activation of proteases [123], and immune cell infiltration resulting in the enzymatic degradation of the mucus barrier[121]. When ripening is premature, these changes can lead to ascending infection, which can trigger in utero inflammation and PTB. Therefore, anything that can induce cervical ripening, or in any way compromise the mucus barrier, can increase risk for PTB in response to secondary bacterial infection.

Very little is known about how viral infection affects cervical function during pregnancy. Since HSV-2 was shown to increase risk of sPTB, we hypothesized that intravaginal herpesvirus infection would affect the function and structure of the cervix, resulting in reduced cervical competency. We discovered that herpesvirus infection increased ER in cervical epithelia and upregulated cervical HA synthesis, in vitro and in vivo. Furthermore, these changes were associated with dramatic remodeling of collagen within the stromal ECM, in vivo, suggesting that viral infection affected the structural integrity of the cervix.

Previously, a study including nearly 700,000 women reported that untreated genital herpes simplex virus-2 (HSV-2) infection nearly doubled the risk of sPTB[124]. Furthermore, in a mouse model of pregnancy, herpesvirus infection significantly increased the risk for PTB in the presence of low levels of bacterial endotoxin, another risk factor. In this model, the cervix was the primary viral target in the reproductive tract [125]. Infection decreased expression of numerous innate immune genes in the cervix and reduced cervical protection from artificial ascending bacterial infection. Based on these data, we hypothesize herpesviruses can increase risk for sPTB by affecting cervical function.

## **Materials and methods**

### *Pregnant mice and infections*

Animals were maintained at Michigan State University's Animal Facility and all procedures were approved by Michigan State University's Institutional Animal Care and Use Committee (IACUC #11-14-198-00). C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME); adult female mice (8–12 wks of age) were mated and confirmed pregnant when vaginal plug was detected. Mice received HSV-2 ( $10^6$ ), MHV68 ( $10^6$ ), or vehicle, intra-vaginally, on E10.5 after sedation with isoflurane. Redness and swelling was observed with mice treated with HSV-2, indicating infection. Mice were humanely sacrificed on E15.5 using CO<sub>2</sub> followed by cervical dislocation. The cervix was flushed with sterile 1XPBS (3x with 30 $\mu$ l) and fixed in 4% PFA overnight. Animal numbers: HSV-2, n=4; MHV68, n=4; control, n=8.

### *Histology*

Cervices were harvested from mice and immediately placed into 4% paraformaldehyde rocking at room temperature overnight. Tissues were then washed in 70% ethanol, placed into Thermo Scientific Excelsior ES tissue processor for routine processing, and embedded in paraffin wax. For immunohistochemical (IHC) analysis of ER protein, 6 $\mu$ m sections underwent antigen retrieval by boiling in sodium citrate buffer and treatment with endogenous biotin inhibitor (X059030-2, Dako, Santa Clara, CA). Tissue sections were incubated with primary antibody (1:100, ER- $\alpha$ , MC20, Santa Cruz Biotechnology, CA) in

antibody diluent (S080981-2, Dako, Santa Clara, CA) overnight at 4C. The following day, tissue was incubated with secondary antibody (ab6720, 1:200, goat anti-rabbit IgG-biotinylated, Abcam, Cambridge, ME) for 1h, treated with an inhibitor of endogenous peroxidase (S200380-2, Dako, Santa Clara, CA), and developed with diaminobenzidine (DAB) substrate-chromogen (K346711-2, Dako, Santa Clara, CA). Negative controls underwent the same protocol but without primary antibody. For collagen staining, 10 $\mu$ m tissue sections were stained with picosirius red (Polysciences Inc, Warrington, PA). Using a 40x objective and polarized light, a photomicrograph was taken of 10 sections, at least 20 $\mu$ m apart, per animal. The optical density (OD) of three non-overlapping sections of each photo was analyzed. Specifically, after photomicrographs were converted to gray scale, they were inverted and OD was calculated using a calibrated threshold and the Rodbard standard curve (NIH Image J software). In this analysis, areas of dark collagen staining have low OD values, and areas with light staining have high OD values. To account for cell density, the OD was divided by cell nuclei/area. Animal numbers per group: HSV-2, n=4; MHV68, n=4; control, n=8.

### Cell culture and treatments

Immortalized human ectocervical cells (ECT1, CRL-2614, ATCC, Grand Island, NY) were cultured in keratinocyte serum free medium (17005-042, Gibco, Grand Island, NY) with bovine pituitary extract and hEGF supplementation as recommended by ATCC under 5% CO<sub>2</sub> at 37°C. Cells were confirmed to be mycoplasma free (13100-01, Southern Biotechnology, Birmingham, Al). Inhibitors included Src inhibitor cocktail, SKI-1/PP1 (ab120839, ab120859, Abcam, Cambridge, ME) resuspended in DMSO (5 $\mu$ M) and an

inhibitor of HA synthesis, 4-methylumbelliferone (4-MU, M1381, Sigma Aldrich, St Louis, MO) resuspended in methanol (600nM). Cells were treated with inhibitors for 1h prior to HSV-2 infection ( $10^6$ ). Supernatants and cells were collected 24 or 48h after HSV-2 infection, as indicated. To infect ECT-1 with HSV-2, cells were inoculated with HSV-2 ( $10^6$ ) in 500  $\mu$ l for 1h prior to addition of 2.5 mL media (protocol for 35mm plate). Results from cell culture experiments are representative of 4 independent experiments.

#### *Virus production and quantification*

MHV68 was passaged on M2-10B4 cells (CRL-1972, ATCC, Grand Island, NY) in DMEM plus 10% FBS. HSV-2 was passaged in Vero Cells (CL-81, ATCC, Grand Island, NY) in DMEM plus 10% FBS. After lysis supernatants were harvested, filtered (0.45  $\mu$ m pore) and titered by 10-fold serial dilutions on confluent monolayers. To detect viral titers in mice, DNA was extracted from the cervix using DNeasy blood and tissue kit (69504, Qiagen, Valencia, CA). 100ng total DNA was then assayed using primers specific for MHV68 (forward primer: 5'-CCA-CTG-AGG-GAC-GTA-TGT-GT-3', reverse primer: 5'-TGG-GAT-CAC-CCA-AGA-AAC-CAC-3') or HSV-2 (forward primer: 5'-GCT-CGA-GTG-CGA-AAA-AAC-GTT-3', reverse primer: 5'-TGC-GGT-TGA-TAA-ACG-CGC-AGT-3'), and compared to a standard curve. Results reported as copies/100ng DNA.

#### *RNA, cDNA synthesis and qPCR*

RNA was extracted from ECT-1 cells using RNeasy RNA extraction kit (74104, Qiagen, Valencia, CA). RNA concentration and purity was analyzed using spectrophotometric analyses of 260/280 ratios with exclusions for samples that were below 1.7. For real-time

quantitative analysis of mRNA, 1 µg of RNA was reverse transcribed for each sample using iScript cDNA synthesis kit (170-8891, Bio-Rad, Hercules, CA). The cDNA was diluted 1:20 in nuclease-free water and 5µl was mixed with SsoAdvanced Universal SYBR green superscript (172-5270, Bio-Rad, Hercules, CA) and gene specific primers for ER-α (forward primer: 5'-GGC-CCC-AGC-TCC-TCC-TCA-T-3', reverse primer: 5'-ACG-TTC-TTG-CAC-TTC-ATG-CTG-TA-3') and GAPDH (forward primer: 5'-AGG-GCT-GCT-TTT-AAC-TCT-GGT-3', reverse primer: 5'-CCC-CAC-TTG-ATT-TTG-GAG-GGA-3'). Samples were evaluated with the Applied Biosystems Q-RT PCR machine. Values were normalized to GAPDH and calculated using delta delta Ct method; delta delta Ct= delta ct treated- delta Ct control; results expressed as fold differences are  $2^{-(\text{average delta delta Ct})}$  for negative delta delta Ct values or  $- (2^{[\text{average delta delta Ct}]})$  for positive delta delta Ct values.

#### Hyaluronic Acid ELISA

Hyaluronic acid concentration was assessed using ELISA (DHYAL0, R&D systems, Minneapolis, MN). ECT1-conditioned medium was diluted 1:40, cervical flushes were diluted 1:160, and samples were assayed according to manufacturer's protocol. Wavelength correction was used by subtracting 540 nm readings from all readings at 450 nm. The subtraction was used to correct for optical imperfections in the plate as recommended by manufacturer.

### Western blot analysis

Cells were lysed in M-PER Mammalian Protein Extraction Reagent buffer (78503, Pierce, Rockford, IL), with HALT protease inhibitor. Total protein concentrations were quantified using BCA assay (23227, Pierce, Rockford, IL). Twenty-five micrograms of total proteins were dissolved in 1X sample buffer, boiled for 5 minutes and separated on a 5-20% SDS-PAGE gel in 1X Tris-Glycine SDS running buffer (Novex, Carlsbad, CA) at a constant voltage of 125V for 2h. The proteins were transferred to PVDF membranes (0.45 µm, Novex, Carlsbad, CA) in an XCell II Blot module apparatus (Novex, Carlsbad, CA) at a constant 25 V for 2hrs. Non-fat milk (NFM) (5%) was used to block non-specific signals and immunoblotting was performed with a 1:1000 dilution of primary antibodies against total Src and phospho-Src-Tyr527 (2105, 32G6, Cell Signaling, Danvers, MA), ER-α (MC20, Santa Cruz Biotechnology, CA), or 1:10,000 dilution of beta-actin (ab16039, Abcam, Cambridge, ME) in 2% NFM at 4°C overnight. Membranes were washed in 1X PBST and a 1:10,000 dilution of goat anti-rabbit or goat anti-mouse IgG-horseradish peroxidase (HRP) conjugate (Cell Signaling, Danvers, Mass) was used as appropriate. Membranes were developed using HRP substrate (Amersham ECL Prime Detection Reagent; General Electric, Buckinghamshire, UK) and immunoreactive proteins were visualized using the Bio-Rad ChemiDoc XRS+.

### Statistical analysis


Differences were determined using analysis of variance (ANOVA) (multiple comparisons, Tukey's test), or independent t-test functions of Graph pad inSTAT statistical software (La

Jolla, CA). A p-value of  $\leq 0.05$  was considered significant, different letters denote significant differences. Data is presented as mean  $\pm$  standard error of the mean (SEM).

## **Results and figures**

### *Cervical viral infection affects stromal tissue organization*

We first determined if viral infection affected the cellular and/or extra-cellular structure of the cervical stroma during pregnancy. Mice were infected with MHV68, HSV2 or vehicle, intra-vaginally, at gestational day (gd)10.5, and cervixes were collected at gd15.5. Tissue was fixed, stained for collagen, and examined using bright light, and polarized light, microscopy. Under bright light, it was readily apparent that infected cervixes had a looser arrangement of collagen fibers compared to controls, as demonstrated by representative sections from cervixes of mice treated with HSV2, MHV68 or vehicle (Figure 1a). To quantify collagen objectively, the sections were first viewed under polarized light and converted to gray scale (Figure 1b). Images were then inverted and OD was calculated using a calibrated threshold and the Rodbard standard curve (NIH Image J). In this analysis, areas of dark collagen staining have low OD values, and areas with light staining have high OD values, and the OD is normalized to cell number by dividing by number of nuclei per  $\mu\text{m}^2$ . The infected cervix tissue had higher OD compared to the controls, indicating the collagen was less dense in infected tissue (Figure 1c), (t-test,  $p=0.0007$ ). The cervical stroma was also less cellular in infected animals, which was quantified by analyzing the number of nuclei per  $\mu\text{m}^2$  (Figure 1d), (t-test,  $p=0.02$ ).



**Figure 1: Cervical viral infection affects stromal tissue organization**


Histological sections from cervixes of animals infected with MHV68, HSV-2 or vehicle were stained with picosirius red to characterize collagen organization. (A) A representative section from pregnant mice infected with HSV2, MHV68 and representative sections from two control mice (VEH) were imaged under bright light microscopy (4x) and shown in gray scale. (B) Representative images from control (VEH) and infected (VIRUS) animals under polarized light and gray scale conversion (40x). (C) Collagen content and structure was quantified by calculating the optical density (OD) using 3 non-overlapping photos from 10 sections per animal, normalized to cell nuclei/μm<sup>2</sup>. Specifically, after photomicrographs were converted to gray scale (as shown

**Figure 1 (cont'd):** in (B)), they were inverted and OD was calculated using a calibrated threshold and the Rodbard standard curve. In this analysis, areas of dark collagen staining have low OD values, and areas with light staining have high OD values (t-test,  $p=.0007$ ). (D) Cell density analysis, represented as the number of nuclei per  $\mu\text{m}^2$  (t-test,  $p=.02$ ). Animal treatments: HSV-2,  $n=4$ ; MHV68,  $n=3$ ; vehicle,  $n=8$ .

### Viral infection increases ER- $\alpha$ protein in cervical epithelial cells

Normally, at term, cervical remodeling is mediated by changes in steroid hormone concentrations within the tissue, characterized by a shift from progesterone to estrogen dominance [126]. Since viral infection induced similar changes in the cervical stroma, we examined how infection affected the known mediators of the local hormonal shift. Initially, the human cervical epithelial cell line, ECT-1, was used to screen the effect of HSV-2 infection on known regulators of cervical endocrinology. While HSV-2 did not affect progesterone receptor (PR), or 17 $\beta$ -hydroxysteroid dehydrogenase (17 $\beta$ -HSD)(data not shown), the infection did increase ER- $\alpha$  (Figure 2a). Furthermore, there was no change in *ESR1* mRNA (Figure 2b), (analysis of variance (ANOVA), n.s.), suggesting HSV-2 stabilized the protein, as opposed to increasing transcription.

We also examined ER- $\alpha$  expression in cervixes from infected and control mice at gd15.5 using immunohistochemistry. In infected mice, there were irregular pockets of cervical epithelium expressing ER- $\alpha$ , which can be identified by the brown positive staining (Figure 2c). The cellular staining pattern suggested the receptor was localized in the cytoplasm, as well as in or around the nucleus of the non-differentiated epithelial cells (NDE), which were small, lacked mucus and resided beneath the differentiated mucosal epithelial cells (DME) (Figure 2c). The DME contained large mucus vacuoles and had little to no positive ER- $\alpha$  staining (Figure 2c). This was in stark contrast to control tissues that had very little, if any, epithelial cells positive for ER- $\alpha$  (Figure 2c).




**Figure 2: Viral infection increases ER-α protein in cervical epithelial cells**

ECT-1 cells were treated with vehicle (VEH) or HSV-2 for 24, 48h and 72h. (A) Representative Western blot analysis of ER-α, and actin loading control. (B) Quantitative PCR was used to analyze ERA mRNA expression in ECT-1 with and without HSV-2 (ANOVA, n.s.). (C) Representative images from control (VEH) and infected (HSV-2) animals analyzed for ER-α protein using immunohistochemistry. NDE, non-differentiated epithelial cells; DME, differentiated mucosal epithelial cells. Figures represent results of 4 independent in vitro experiments. Animal treatments: HSV-2, n=4; MHV68, n=3; vehicle, n=8.

*Hyaluronic acid is increased by HSV-2 in the pregnant cervix and ECT1 cells*

We then considered how the virus, and the associated increase in ER- $\alpha$  protein in the epithelia, might be related to the changes in the tissue stroma. Hyaluronic acid (HA) is an important component of the cervical mucus barrier and the stromal ECM. It is also regulated by estradiol and increases at the end of gestation. Therefore, we analyzed cervical flushes from pregnant mice with and without viral infection and discovered HA was significantly increased in the infected mice (Figure 3a, t-test,  $p=.012$ ). Similarly, HSV-2 increased HA in ECT-1 conditioned medium at 48h post-infection (Figure 3b), (24h NT vs HSV2: t-test, n.s.; 48h NT vs HSV2: t-test,  $p=.017$ ).




**Figure 3: Hyaluronic acid is increased by HSV-2 in the pregnant cervix and ECT1**

(A) Hyaluronic acid was quantified at gd15.5 in cervical flushes from infected and control animals using ELISA (t-test,  $p=.012$ ). (B) Hyaluronic acid was quantified in ECT-1 conditioned medium 24 or 48h after treatment with vehicle or HSV-2 using ELISA (24h Veh vs Virus: t-test, n.s.; 48h Veh vs Virus: t-test,  $p=.017$ ). Animal treatments: HSV-2,  $n=4$ ; MHV68,  $n=3$ ; vehicle,  $n=8$ . HSV-2 and MHV68 treatments analyzed together compared to vehicle. In vitro results represent 3-4 independent experiments.

### Herpes simplex virus-2 activation of Src kinase stabilizes ER- $\alpha$ and regulates HA

We next determined how HSV-2 might stabilize ER- $\alpha$  protein and/or induce changes in HA expression in cervical epithelial cells. The tyrosine kinase Src was previously shown to be activated by toll-like receptor signaling following viral infection [125], and Chu *et al.* showed it to interact with ER- $\alpha$ , therefore we first tested its role in HSV-associated ER- $\alpha$  stabilization. First we treated ECT-1 with HSV-2 and measured phosphorylation of Src-Tyr527 at multiple time points from 30m up to 8h post-infection. This phosphorylation site is an inhibitor of function and acts as the primary regulator of Src, therefore loss of phosphorylation at Tyr527 indicates Src is in its active form. We found that Src Tyr527 phosphorylation was not changed at early timepoints following infection (30m-2h, data not shown), but viral infection reduced phosphorylation, or activated Src, at 6h and 8h post-infection (Figure 4a). To determine if Src could also affect ER- $\alpha$ , ECT-1 cells were treated with Src inhibitor, SKI/PP1, which resulted in decreased ER- $\alpha$  protein (Figure 4b). To test if HSV-associated changes in ER- $\alpha$  were mediated by Src kinase, we inhibited Src (SKI-PP1) prior to HSV-2 infection and again measured ER- $\alpha$  protein. When ECT-1 cells were treated with the Src inhibitor, HSV-2 infection no longer caused an increase in ER- $\alpha$  protein (Figure 4c) suggesting HSV-2 mediates ER- $\alpha$  protein stability by activating Src kinase in cervical epithelial cells. Finally, we tested how activation of Src affected HSV-associated changes in HA. When we infected ECT-1 with HSV-2 in the presence of Src inhibitors (SKI-PP1), the virus-associated increase in HA was diminished (Figure 4d), (ANOVA; Tukey's multiple comparison; a<b, p=.012; a>c, p=.026; b>c, p=.0003). Therefore, Src kinase could be an important mediator of the cervical response to HSV-2.




**Figure 4: Herpes simplex virus-2 regulates ER- $\alpha$  and HA via Src kinase activation**

(A) Src kinase activation was characterized in ECT-1 cells 4, 6, and 8h post-infection with HSV-2 using Western blot analysis with an antibody specific for Src Tyr527 phosphorylation or total Src. (B) ECT-1 cells were treated with vehicle (DMSO) or Src inhibitor (SKI/PP1) and ER- $\alpha$  protein was quantified using Western blot analysis. (C) ECT-1 cells were treated with HSV-2, HSV-2 and DMSO, or HSV-2 and Src kinase inhibitor, and ER- $\alpha$  protein was quantified using Western blot analysis. (D) ECT-1 were treated with vehicle (DMSO), vehicle and HSV-2, or Src inhibitor (SKI-PP1) and HSV-2

**Figure 4 (cont'd):** for 24h and HA was quantified in the conditioned medium using ELISA (ANOVA with Tukey's multiple comparison;  $a < b$ ,  $p = .012$ ;  $a > c$ ,  $p = .026$ ;  $b > c$ ,  $p = .0003$ ). Figures represent results of 4 independent in vitro experiments.

### *Hyaluronic acid mediates HSV-2 infection*

Interestingly, HA has also been shown to facilitate viral infection of host cells [127]. Therefore, since HSV-2 upregulated HA, we tested its role in mediating HSV-2 infection of cervical epithelial cells. ECT-1 cells were treated with 4-methylumbelliferone (4-MU), an inhibitor of HA synthesis, which resulted in down-regulation of HA (Figure 5a), (t-test,  $p=.003$ ). Cells were then infected with HSV-2, and viral titers were analyzed 24h post-infection by measuring gene copy number. Inhibition of HA resulted in a drastic decrease in HSV-2 infection (Figure 5b), (t-test,  $p=.019$ ). Inhibition of Src kinase (SKI-PP1) also resulted in a similar decrease in HSV-2 infection (Figure 5c), (t-test,  $p=.006$ ). Therefore, the HSV-associated increases in HA could result in increased susceptibility to epithelial cell infection, in addition to the potential changes in cervix tissue structure.



**Figure 5: Hyaluronic acid mediates HSV-2 infection**

(A) ECT-1 cells were treated with vehicle (VEH, methanol) or 4-MU, an inhibitor of HA synthesis, and HA was quantified in conditioned medium (t-test,  $p=0.003$ ). (B) ECT-1 cells were treated with vehicle (VEH) or 4-MU preceding HSV-2 infection, and viral copy number was analyzed using qPCR (t-test,  $p=0.019$ ). ECT-1 were treated with vehicle (VEH) or Src inhibitor (SKI-PP1) preceding HSV-2 infection and HSV-2 copy number was analyzed using qPCR (t-test;  $p=0.006$ ). Figures represent results of 4 independent in vitro experiments.

**CHAPTER 3:**  
**CONCLUSIONS AND DISCUSSION**

For the first time, to our knowledge, we report that intra-vaginal herpesvirus infection causes cervical remodeling in pregnant mice. Herpesvirus infection of the cervical epithelium was associated with increased expression of ER- $\alpha$ , increased cell proliferation, and upregulation of HA synthesis and/or secretion. These changes were associated with significant disorganization and/or loss of collagen within the cervical stroma. Using ECT-1 cells, we discovered that HSV-2 activated Src kinase, which mediated the increase in ER and HA. Infection with HSV-2, activation of Src, and increased HA also increased the susceptibility of cervical epithelial cells to HSV-2 infection. These results demonstrate viral infection can significantly change the cervix during pregnancy. We propose viral infection can induce cervical insufficiency, which increases risk of ascending infection, intra-amniotic inflammation and preterm labor[128].

Cervical ripening in response to hormones has been best characterized in rodent models. Typically, and in the absence of bacterial infection, cervical ripening is initiated by the switch from high P<sub>4</sub> to high E<sub>2</sub> at the end of pregnancy. Previously this raised concerns about the model, since rodents experience a sharp decline in circulating P<sub>4</sub> at the end of pregnancy, while P<sub>4</sub> is maintained in women. These concerns were in some way overcome by the discovery that, in both species, cervical ripening was regulated by changes in local hormone metabolism, which resulted in the loss of P<sub>4</sub> within the tissue. In rodents, upregulation of SRD5 $\alpha$ 1 decreases P<sub>4</sub> concentration, while in humans downregulation of 17 $\beta$ -HSD reduces P<sub>4</sub> and increased E<sub>2</sub> synthesis in the cervix. Therefore, since we considered the rodent model reasonable, we used a mouse model to study herpesvirus infection of the cervix during pregnancy.


We were intrigued to discover viral infection increased ER- $\alpha$  in cervical epithelial cells. Availability of ER has been shown to be directly associated with E<sub>2</sub> function in multiple cell types, therefore viral infection likely increases E<sub>2</sub> sensitivity in the epithelium. We also observed dramatic reorganization of the cervical stroma, including reduced cell density and loosening of the collagen fiber network. These changes can be triggered by the hormone environment, or by an inflammatory cascade mediated by immune cells [129]. We speculate that viral infection could affect the cervix both ways, by increasing local E<sub>2</sub>-sensitivity and activating immune cells. Future investigation into the mechanism of virus-induced cervical changes will be important for development of clinical interventions.

Hyaluronic acid synthesis is also associated with hormone changes [130], and infection [62], induced cervical ripening and is a result of increased expression of HA synthase-2 or -3 (*HAS2/3*). Interestingly, *HAS2* is positively regulated by estradiol in the cervix[131], which is relevant to our study because HA was increased in infected cervixes, which was associated with the increased ER- $\alpha$  in cervical epithelia. We could not use the ECT-1 to determine the role of ER in HSV-induced HA synthesis because cervical epithelial cells do not properly respond to E<sub>2</sub> without the stroma, but we did determine HA synthesis was dependent on Src kinase activation following viral infection. Therefore, Src kinase could be an important mediator of the virus-associated changes in cervical function. Although the role of ER in our model is still unknown, we hypothesize it mediates some of the cervical changes downstream of viral infection and Src activation. This is being tested in ongoing in vivo studies of infection with an ER antagonist.

Finally, we tried to identify factors that might affect the susceptibility of the cervix to HSV-2 infection. Herpes simplex virus-2 can readily infect primary human cervical epithelial cells, and infection can be reduced using the antiviral drug, Acyclovir, or the ligand for toll-like receptor-3, Poly (I:C) [132]. Infection can also be affected by sex-hormone treatment. In primary human epithelial and stromal cell co-cultures, treatment with E<sub>2</sub> resulted in increased infection while P<sub>4</sub> decreased HSV-2 infectivity [132]. In a mouse model, there was no susceptibility to genital infection during estrus (high E<sub>2</sub>), while animals in diestrus or treated with P<sub>4</sub> had high susceptibility to HSV-2 [133, 134]. It is still unclear how genital tract infection is affected by sex hormones and susceptibility to HSV-2 during pregnancy has not been established. Interestingly, HA and other glycosaminoglycans, such as heparin sulfate, are established mediators of herpesvirus viral entry into host cells. We determined that HA did affect HSV-2 infection of cervical epithelial cells. Indeed, loss of HA by direct inhibition with 4-MU or inhibition of Src kinase drastically reduced HSV-2 infection of ECT-1. Collectively, the data suggests that HSV-2 infection upregulates HA, which in turn, further increases viral susceptibility.

In conclusion, we propose that virus-associated activation of Src kinase, and the associated stabilization of ER, and HA synthesis in the epithelium, affects the structure of the cervical stroma and further increases the susceptibility to infection (Figure 6). Ongoing studies are investigating the causal link between the virus-associated changes in the epithelia and the stromal remodeling. Also, while not addressed in this study, local immune cells are also affected by cervical viral infection, and it is likely that these cells also contribute to the remodeling of the ECM. Studies like this are necessary to understand how viral infection could increase the risk for sPTB in women. Based on these

results, we could predict that HSV-2 infection might weaken the cervix or even induce premature cervical ripening in some women. It is our hope that understanding the mechanism of virus-induced cervical remodeling will help us provide targets for clinical intervention.



**Figure 6: Proposed model of cervical viral infection during pregnancy**

Herpesvirus infection of the pregnant cervix bind surface receptors, such as integrins and HA, resulting in viral entry. Infection causes activation of Src kinase, which stabilizes ER, increasing ER concentration and potentially estrogen sensitivity. These changes result in increased HA expression on the surface of epithelial cells, which in turn, increases viral entry into the cells. Increased soluble HA affects the structure of the cervical stroma. These changes are associated with decreased collagen and cellular density of the stroma.

As we continue this investigation we hope to address several remaining questions. One of the primary questions is the potential role that immune cells are playing in remodeling after the initial infection. If immune cells are recruited to the cervix, what is their function there? We want to study MMPs and their potential role in the changing collagen. Understanding if MMPs are being created immune cells, fibroblasts, or both could create potential for development of therapeutic treatments for at-risk women. Better understanding the role of estrogen and its receptors can be achieved with utilizing an estrogen receptor antagonist, and would allow us to both identify critical factors controlled by estrogen and turn to the potential of rescuing a phenotype of term-birth. Finally, to address the idea of PTB as a syndrome, we could attempt to test viral infections with other causes of preterm birth in mice.

## REFERENCES

## REFERENCES

1. Howson, C.P., et al., *Born too soon: preterm birth matters*. *Reprod Health*, 2013. **10 Suppl 1**: p. S1.
2. Blencowe, H., et al., *Born too soon: the global epidemiology of 15 million preterm births*. *Reprod Health*, 2013. **10 Suppl 1**: p. S2.
3. Frey, H.A. and M.A. Klebanoff, *The epidemiology, etiology, and costs of preterm birth*. *Semin Fetal Neonatal Med*, 2016. **21**(2): p. 68-73.
4. Harrison, M.S. and R.L. Goldenberg, *Global burden of prematurity*. *Semin Fetal Neonatal Med*, 2016. **21**(2): p. 74-9.
5. Centers for Disease Control and Prevention, *Preterm Birth*. 2016 [cited 2017 March 23]; Available from: <https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm>.
6. World Health Organization, *Preterm Birth*. 2016 [cited 2017 23 March]; Available from: <http://www.who.int/mediacentre/factsheets/fs363/en/>.
7. Blencowe, H., et al., *National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications*. *Lancet*, 2012. **379**(9832): p. 2162-72.
8. Liu, L., et al., *Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis*. *Lancet*, 2015. **385**(9966): p. 430-40.
9. Simmons, L.E., et al., *Preventing preterm birth and neonatal mortality: exploring the epidemiology, causes, and interventions*. *Semin Perinatol*, 2010. **34**(6): p. 408-15.
10. Marlow, N., et al., *Neurologic and developmental disability at six years of age after extremely preterm birth*. *N Engl J Med*, 2005. **352**(1): p. 9-19.
11. Rodriguez, R.J., *Management of respiratory distress syndrome: an update*. *Respir Care*, 2003. **48**(3): p. 279-86; discussion 286-7.
12. Garg, M. and S.U. Devaskar, *Glucose metabolism in the late preterm infant*. *Clin Perinatol*, 2006. **33**(4): p. 853-70; abstract ix-x.

13. Rehman, M.U. and H. Narchi, *Metabolic bone disease in the preterm infant: Current state and future directions*. World J Methodol, 2015. **5**(3): p. 115-21.
14. Barrington, K.J., *Hypotension and shock in the preterm infant*. Semin Fetal Neonatal Med, 2008. **13**(1): p. 16-23.
15. Sharma, A.A., et al., *The developing human preterm neonatal immune system: a case for more research in this area*. Clin Immunol, 2012. **145**(1): p. 61-8.
16. R.E. Behrman and A.S., *Preterm Birth: Causes, Consequences, and Prevention*. Butler, Editors. 2007: Washington (DC).
17. World Health Organization, *Born Too Soon: The Global Action Report on Preterm Birth*. 2012.
18. Goldenberg, R.L., et al., *Epidemiology and causes of preterm birth*. Lancet, 2008. **371**(9606): p. 75-84.
19. Moutquin, J.M., *Classification and heterogeneity of preterm birth*. Bjog, 2003. **110 Suppl 20**: p. 30-3.
20. Papiernik, E., et al., *Precocious cervical ripening and preterm labor*. Obstet Gynecol, 1986. **67**(2): p. 238-42.
21. Lamont, R.F., *Infection in the prediction and antibiotics in the prevention of spontaneous preterm labour and preterm birth*. Bjog, 2003. **110 Suppl 20**: p. 71-5.
22. Romero, R., M. Mazor, and B. Tartakovsky, *Systemic administration of interleukin-1 induces preterm parturition in mice*. Am J Obstet Gynecol, 1991. **165**(4 Pt 1): p. 969-71.
23. Elovitz, M.A., et al., *A new model for inflammation-induced preterm birth: the role of platelet-activating factor and Toll-like receptor-4*. Am J Pathol, 2003. **163**(5): p. 2103-11.
24. Davies, J.K., et al., *Histologic inflammation in the maternal and fetal compartments in a rabbit model of acute intra-amniotic infection*. Am J Obstet Gynecol, 2000. **183**(5): p. 1088-93.
25. Sadowsky, D.W., et al., *Dexamethasone or interleukin-10 blocks interleukin-1beta-induced uterine contractions in pregnant rhesus monkeys*. Am J Obstet Gynecol, 2003. **188**(1): p. 252-63.

26. Schlafer, D.H., et al., *Effect of Salmonella endotoxin administered to the pregnant sheep at 133-142 days gestation on fetal oxygenation, maternal and fetal adrenocorticotrophic hormone and cortisol, and maternal plasma tumor necrosis factor alpha concentrations*. Biol Reprod, 1994. **50**(6): p. 1297-302.
27. Ilievski, V. and E. Hirsch, *Synergy between viral and bacterial toll-like receptors leads to amplification of inflammatory responses and preterm labor in the mouse*. Biol Reprod, 2010. **83**(5): p. 767-73.
28. Bennett, W.A., et al., *Intrauterine endotoxin infusion in rat pregnancy induces preterm delivery and increases placental prostaglandin F2alpha metabolite levels*. Am J Obstet Gynecol, 2000. **182**(6): p. 1496-501.
29. Agrawal, V. and E. Hirsch, *Intrauterine infection and preterm labor*. Semin Fetal Neonatal Med, 2012. **17**(1): p. 12-9.
30. Garfield, R.E., et al., *Modulation of rat uterine contractility by mast cells and their mediators*. Am J Obstet Gynecol, 2000. **183**(1): p. 118-25.
31. Vink, J. and H. Feltovich, *Cervical etiology of spontaneous preterm birth*. Semin Fetal Neonatal Med, 2016. **21**(2): p. 106-12.
32. Mancuso, M.S., et al., *Cervical funneling: effect on gestational length and ultrasound-indicated cerclage in high-risk women*. Am J Obstet Gynecol, 2010. **203**(3): p. 259.e1-5.
33. Hassan, S.S., et al., *Patients with an ultrasonographic cervical length < or =15 mm have nearly a 50% risk of early spontaneous preterm delivery*. Am J Obstet Gynecol, 2000. **182**(6): p. 1458-67.
34. Hertelendy, F. and T. Zakar, *Prostaglandins and the myometrium and cervix*. Prostaglandins Leukot Essent Fatty Acids, 2004. **70**(2): p. 207-22.
35. Platz-Christensen, J.J., et al., *Prostaglandin E and F2 alpha concentration in the cervical mucus and mechanism of cervical ripening*. Prostaglandins, 1997. **53**(4): p. 253-61.
36. Toth, M., J. Rehnstrom, and A.R. Fuchs, *Prostaglandins E and F in cervical mucus of pregnant women*. Am J Perinatol, 1989. **6**(2): p. 142-4.
37. Timmons, B.C., et al., *Dynamic changes in the cervical epithelial tight junction complex and differentiation occur during cervical ripening and parturition*. Endocrinology, 2007. **148**(3): p. 1278-87.

38. Timmons, B., M. Akins, and M. Mahendroo, *Cervical remodeling during pregnancy and parturition*. Trends Endocrinol Metab, 2010. **21**(6): p. 353-61.
39. Read, C.P., et al., *Cervical remodeling during pregnancy and parturition: molecular characterization of the softening phase in mice*. Reproduction, 2007. **134**(2): p. 327-40.
40. Leppert, P.C., *Anatomy and physiology of cervical ripening*. Clin Obstet Gynecol, 1995. **38**(2): p. 267-79.
41. Akins, M.L., et al., *Cervical softening during pregnancy: regulated changes in collagen cross-linking and composition of matricellular proteins in the mouse*. Biol Reprod, 2011. **84**(5): p. 1053-62.
42. van der Slot, A.J., et al., *Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis*. J Biol Chem, 2003. **278**(42): p. 40967-72.
43. Kjellef, S., *The trefoil factor family - small peptides with multiple functionalities*. Cell Mol Life Sci, 2009. **66**(8): p. 1350-69.
44. Descargues, P., et al., *Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity*. Nat Genet, 2005. **37**(1): p. 56-65.
45. van Engelen, E., et al., *MMP-2 expression precedes the final ripening process of the bovine cervix*. Mol Reprod Dev, 2008. **75**(11): p. 1669-77.
46. Norman, M., et al., *Proteoglycan metabolism in the connective tissue of pregnant and non-pregnant human cervix. An in vitro study*. Biochem J, 1991. **275** ( Pt 2): p. 515-20.
47. Anum, E.A., et al., *Connective tissue and related disorders and preterm birth: clues to genes contributing to prematurity*. Placenta, 2009. **30**(3): p. 207-15.
48. Westergren-Thorsson, G., et al., *Differential expressions of mRNA for proteoglycans, collagens and transforming growth factor-beta in the human cervix during pregnancy and involution*. Biochim Biophys Acta, 1998. **1406**(2): p. 203-13.
49. Spillmann, D., D. Witt, and U. Lindahl, *Defining the interleukin-8-binding domain of heparan sulfate*. J Biol Chem, 1998. **273**(25): p. 15487-93.

50. Burgess, J.K., et al., *The extracellular matrix - the under-recognized element in lung disease?* J Pathol, 2016. **240**(4): p. 397-409.
51. Lindahl, U., et al., *More to "heparin" than anticoagulation.* Thromb Res, 1994. **75**(1): p. 1-32.
52. Cadene, M., et al., *Influence of low molecular mass heparin on the kinetics of neutrophil elastase inhibition by mucus proteinase inhibitor.* J Biol Chem, 1995. **270**(22): p. 13204-9.
53. Tanaka, Y., D.H. Adams, and S. Shaw, *Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes.* Immunol Today, 1993. **14**(3): p. 111-5.
54. Sennstrom, M.B., et al., *Human cervical ripening, an inflammatory process mediated by cytokines.* Mol Hum Reprod, 2000. **6**(4): p. 375-81.
55. Straach, K.J., et al., *Regulation of hyaluronan expression during cervical ripening.* Glycobiology, 2005. **15**(1): p. 55-65.
56. Chen, W.Y. and G. Abatangelo, *Functions of hyaluronan in wound repair.* Wound Repair Regen, 1999. **7**(2): p. 79-89.
57. McDevitt, C.A., J. Marcelino, and L. Tucker, *Interaction of intact type VI collagen with hyaluronan.* FEBS Lett, 1991. **294**(3): p. 167-70.
58. Tesar, B.M., et al., *The role of hyaluronan degradation products as innate alloimmune agonists.* Am J Transplant, 2006. **6**(11): p. 2622-35.
59. Almond, A., *Hyaluronan.* Cell Mol Life Sci, 2007. **64**(13): p. 1591-6.
60. Ruscheinsky, M., C. De la Motte, and M. Mahendroo, *Hyaluronan and its binding proteins during cervical ripening and parturition: dynamic changes in size, distribution and temporal sequence.* Matrix Biol, 2008. **27**(5): p. 487-97.
61. Winkler, M. and W. Rath, *Changes in the cervical extracellular matrix during pregnancy and parturition.* J Perinat Med, 1999. **27**(1): p. 45-60.
62. Akgul, Y., et al., *Hyaluronan in cervical epithelia protects against infection-mediated preterm birth.* J Clin Invest, 2014. **124**(12): p. 5481-9.

63. Jayasooriya, G.S. and R.F. Lamont, *The use of progesterone and other progestational agents to prevent spontaneous preterm labour and preterm birth*. Expert Opin Pharmacother, 2009. **10**(6): p. 1007-16.
64. Kirby, M.A., et al., *Progesterone Receptor-Mediated Actions Regulate Remodeling of the Cervix in Preparation for Preterm Parturition*. Reprod Sci, 2016. **23**(11): p. 1473-1483.
65. Mahendroo, M., et al., *The Parturition Defect in Steroid 5 $\alpha$ -Reductase Type 1 Knockout Mice Is Due to Impaired Cervical Ripening*. Molecular Endocrinology, 1999. **13**: p. 981-992.
66. Andersson, S., et al., *Estrogen and progesterone metabolism in the cervix during pregnancy and parturition*. J Clin Endocrinol Metab, 2008. **93**(6): p. 2366-74.
67. Mitchell, B.F. and S. Wong, *Changes in 17 beta,20 alpha-hydroxysteroid dehydrogenase activity supporting an increase in the estrogen/progesterone ratio of human fetal membranes at parturition*. Am J Obstet Gynecol, 1993. **168**(5): p. 1377-85.
68. Wu, L., et al., *Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity*. J Biol Chem, 1993. **268**(17): p. 12964-9.
69. Mahendroo, M.S., et al., *The parturition defect in steroid 5alpha-reductase type 1 knockout mice is due to impaired cervical ripening*. Mol Endocrinol, 1999. **13**(6): p. 981-92.
70. Saito, Y., S. Takahashi, and M. Maki, *In vitro effect of some free estrogens or estrogen precursors on collagenase activity of uterine cervix*. Acta Obstet Gynaecol Jpn, 1981. **33**(6): p. 827-32.
71. Yoshida, K., et al., *Effect of dehydroepiandrosterone sulphate, oestrogens and prostaglandins on collagen metabolism in human cervical tissue in relation to cervical ripening*. J Int Med Res, 1993. **21**(1): p. 26-35.
72. Rajabi, M.R., S. Solomon, and A.R. Poole, *Activation of protein kinase C stimulates collagenase production by cultured cells of the cervix of the pregnant guinea pig*. Am J Obstet Gynecol, 1992. **167**(1): p. 194-200.

73. Rajabi, M., S. Solomon, and A.R. Poole, *Hormonal regulation of interstitial collagenase in the uterine cervix of the pregnant guinea pig*. Endocrinology, 1991. **128**(2): p. 863-71.
74. Rajabi, M.R., et al., *Immunochemical and immunohistochemical evidence of estrogen-mediated collagenolysis as a mechanism of cervical dilatation in the guinea pig at parturition*. Endocrinology, 1991. **128**(1): p. 371-8.
75. Markiewicz, M., et al., *A role for estrogen receptor-alpha and estrogen receptor-beta in collagen biosynthesis in mouse skin*. J Invest Dermatol, 2013. **133**(1): p. 120-7.
76. Gomez-Lopez, N., et al., *Immune cells in term and preterm labor*. Cell Mol Immunol, 2014. **11**(6): p. 571-81.
77. Kelly, A.J., J. Kavanagh, and J. Thomas, *Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term*. Cochrane Database Syst Rev, 2001(2): p. Cd003101.
78. Kelly, R.W., *Pregnancy maintenance and parturition: the role of prostaglandin in manipulating the immune and inflammatory response*. Endocr Rev, 1994. **15**(5): p. 684-706.
79. Norman, M., G. Ekman, and A. Malmstrom, *Prostaglandin E2-induced ripening of the human cervix involves changes in proteoglycan metabolism*. Obstet Gynecol, 1993. **82**(6): p. 1013-20.
80. Holt, R., et al., *The molecular mechanisms of cervical ripening differ between term and preterm birth*. Endocrinology, 2011. **152**(3): p. 1036-46.
81. G Liggins, D.E., ABM Anderson, *Cervical Ripening as an inflammatory reaction*. The Cervix in Pregnancy and Labour; Clinical and Biochemical Investigation, 1981.
82. Junqueira, L.C., et al., *Morphologic and histochemical evidence for the occurrence of collagenolysis and for the role of neutrophilic polymorphonuclear leukocytes during cervical dilation*. Am J Obstet Gynecol, 1980. **138**(3): p. 273-81.
83. Osmers, R., et al., *Origin of cervical collagenase during parturition*. Am J Obstet Gynecol, 1992. **166**(5): p. 1455-60.

84. Winkler, M., et al., *Parturition at term: parallel increases in interleukin-8 and proteinase concentrations and neutrophil count in the lower uterine segment*. Hum Reprod, 1999. **14**(4): p. 1096-100.
85. Yellon, S.M., C.A. Ebner, and M.A. Elovitz, *Medroxyprogesterone acetate modulates remodeling, immune cell census, and nerve fibers in the cervix of a mouse model for inflammation-induced preterm birth*. Reprod Sci, 2009. **16**(3): p. 257-64.
86. Owiny, J.R., et al., *Leukocytic invasion of the ovine cervix at parturition*. J Soc Gynecol Investig, 1995. **2**(4): p. 593-6.
87. Sakamoto, Y., et al., *Macrophages and not granulocytes are involved in cervical ripening*. J Reprod Immunol, 2005. **66**(2): p. 161-73.
88. Timmons, B.C. and M.S. Mahendroo, *Timing of neutrophil activation and expression of proinflammatory markers do not support a role for neutrophils in cervical ripening in the mouse*. Biol Reprod, 2006. **74**(2): p. 236-45.
89. Mackler, A.M., et al., *Macrophage trafficking in the uterus and cervix precedes parturition in the mouse*. Biol Reprod, 1999. **61**(4): p. 879-83.
90. Dobyns, A.E., et al., *Macrophage gene expression associated with remodeling of the prepartum rat cervix: microarray and pathway analyses*. PLoS One, 2015. **10**(3): p. e0119782.
91. Yellon, S.M., C.A. Ebner, and Y. Sugimoto, *Parturition and recruitment of macrophages in cervix of mice lacking the prostaglandin F receptor*. Biol Reprod, 2008. **78**(3): p. 438-44.
92. Gonzalez, J.M., et al., *Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice*. Am J Pathol, 2011. **179**(2): p. 838-49.
93. Huang, Q.T., et al., *Can HPV vaccine have other health benefits more than cancer prevention? A systematic review of association between cervical HPV infection and preterm birth*. J Clin Virol, 2014. **61**(3): p. 321-8.
94. Li, D.K., et al., *Genital herpes and its treatment in relation to preterm delivery*. Am J Epidemiol, 2014. **180**(11): p. 1109-17.
95. Nakubulwa, S., et al., *Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric*

- outcomes: a double-blind randomised placebo-controlled trial.* *Reprod Health*, 2017. **14**(1): p. 31.
96. Brown, Z.A., et al., *Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor.* *Obstet Gynecol*, 1996. **87**(4): p. 483-8.
  97. Cardenas, I., et al., *Placental viral infection sensitizes to endotoxin-induced pre-term labor: a double hit hypothesis.* *Am J Reprod Immunol*, 2011. **65**(2): p. 110-7.
  98. Looker, K.J., et al., *Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012.* *PLoS One*, 2015. **10**(10): p. e0140765.
  99. Looker, K.J., et al., *Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012.* *PLoS One*, 2015. **10**(1): p. e114989.
  100. Chayavichitsilp, P., et al., *Herpes simplex.* *Pediatr Rev*, 2009. **30**(4): p. 119-29; quiz 130.
  101. Staras, S.A., et al., *Seroprevalence of cytomegalovirus infection in the United States, 1988-1994.* *Clin Infect Dis*, 2006. **43**(9): p. 1143-51.
  102. Wald, A., *Genital HSV-1 infections.* *Sex Transm Infect*, 2006. **82**(3): p. 189-90.
  103. Nicoll, M.P., J.T. Proenca, and S. Efstathiou, *The molecular basis of herpes simplex virus latency.* *FEMS Microbiol Rev*, 2012. **36**(3): p. 684-705.
  104. Grinde, B., *Herpesviruses: latency and reactivation - viral strategies and host response.* *J Oral Microbiol*, 2013. **5**.
  105. Wald, A., et al., *Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.* *J Clin Invest*, 1997. **99**(5): p. 1092-7.
  106. Crespi, C.M., et al., *Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling.* *Sex Transm Infect*, 2007. **83**(5): p. 359-64.
  107. Wald, A., et al., *Virologic characteristics of subclinical and symptomatic genital herpes infections.* *N Engl J Med*, 1995. **333**(12): p. 770-5.
  108. Azwa, A. and S.E. Barton, *Aspects of herpes simplex virus: a clinical review.* *J Fam Plann Reprod Health Care*, 2009. **35**(4): p. 237-42.

109. Cheshenko, N., et al., *Herpes simplex virus type 2 glycoprotein H interacts with integrin alphavbeta3 to facilitate viral entry and calcium signaling in human genital tract epithelial cells*. J Virol, 2014. **88**(17): p. 10026-38.
110. Altgarde, N., et al., *Mucin-like Region of Herpes Simplex Virus Type 1 Attachment Protein Glycoprotein C (gC) Modulates the Virus-Glycosaminoglycan Interaction*. J Biol Chem, 2015. **290**(35): p. 21473-85.
111. Liang, Y. and B. Roizman, *State and role of SRC family kinases in replication of herpes simplex virus 1*. J Virol, 2006. **80**(7): p. 3349-59.
112. Wagner, M.J. and J.R. Smiley, *Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling*. J Virol, 2011. **85**(6): p. 2803-12.
113. Iams, J.D., et al., *Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth*. Lancet, 2008. **371**(9607): p. 164-75.
114. Romero, R., S.K. Dey, and S.J. Fisher, *Preterm labor: one syndrome, many causes*. Science, 2014. **345**(6198): p. 760-5.
115. Rubens, C.E., et al., *Prevention of preterm birth: Harnessing science to address the global epidemic*. Science Translational Medicine, 2014. **6**(262): p. 262sr5.
116. Muglia, L. and M. Katz, *The Enigma of Spontaneous Preterm Birth*. New England Journal of Medicine, 2010. **362**: p. 529-535.
117. Lawn, J. and M. Kinney, *Preterm Birth: Now the Leading Cause of Child Death Worldwide*. Sci Transl Med, 2014. **6**: p. 263ed21.
118. Goldenberg, R.L., et al., *Epidemiology and causes of preterm birth*. The Lancet, 2008. **371**(9606): p. 75-84.
119. Ekman, G., et al., *Cervical collagen: an important regulator of cervical function in term labor*. Obstet Gynecol, 1986. **67**(5): p. 633-6.
120. Ogawa, M., et al., *The role of cytokines in cervical ripening: correlations between the concentrations of cytokines and hyaluronic acid in cervical mucus and the induction of hyaluronic acid production by inflammatory cytokines by human cervical fibroblasts*. Am J Obstet Gynecol, 1998. **179**(1): p. 105-10.
121. Akgul, Y., et al., *Hyaluronan in cervical epithelia protects against infection-mediated preterm birth*. J Clin Invest, 2014.

122. Lee, H.Y., et al., *The extent to which relaxin promotes proliferation and inhibits apoptosis of cervical epithelial and stromal cells is greatest during late pregnancy in rats*. *Endocrinology*, 2005. **146**(1): p. 511-8.
123. Mogami, H., et al., *Fetal fibronectin signaling induces matrix metalloproteases and cyclooxygenase-2 (COX-2) in amnion cells and preterm birth in mice*. *J Biol Chem*, 2013. **288**(3): p. 1953-66.
124. Li, D.K., et al., *Genital Herpes and Its Treatment in Relation to Preterm Delivery*. *Am J Epidemiol*, 2014.
125. Racicot, K., et al., *Viral infection of the pregnant cervix predisposes to ascending bacterial infection*. *J Immunol*, 2013. **191**(2): p. 934-41.
126. Kumar, P. and N. Magon, *Hormones in pregnancy*. *Niger Med J*, 2012. **53**(4): p. 179-83.
127. Gazzola, R., L. Pasini, and M. Cavallini, *Herpes virus outbreaks after dermal hyaluronic acid filler injections*. *Aesthet Surg J*, 2012. **32**(6): p. 770-2.
128. Lee, S.E., et al., *The frequency and significance of intraamniotic inflammation in patients with cervical insufficiency*. *Am J Obstet Gynecol*, 2008. **198**(6): p. 633 e1-8.
129. Gonzalez, J.M., et al., *Preterm and term cervical ripening in CD1 Mice (Mus musculus): similar or divergent molecular mechanisms?* *Biol Reprod*, 2009. **81**(6): p. 1226-32.
130. Uzuka, M., et al., *The mechanism of estrogen-induced increase in hyaluronic acid biosynthesis, with special reference to estrogen receptor in the mouse skin*. *Biochim Biophys Acta*, 1980. **627**(2): p. 199-206.
131. Akgul, Y., et al., *Dynamic changes in cervical glycosaminoglycan composition during normal pregnancy and preterm birth*. *Endocrinology*, 2012. **153**(7): p. 3493-503.
132. MacDonald, E.M., et al., *Susceptibility of human female primary genital epithelial cells to herpes simplex virus, type-2 and the effect of TLR3 ligand and sex hormones on infection*. *Biol Reprod*, 2007. **77**(6): p. 1049-59.
133. Kaushic, C., et al., *Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection*. *Journal of Virology*, 2003. **77**(8): p. 4558-4565.

134. Teepe, A., et al., *Effect of the estrous cycle on the susceptibility of female mice to intravaginal inoculation of herpes simplex virus type 2*. Antiviral Research, 1990. **14**(4-5): p. 227-235.